Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $42.00 target price on the biotechnology company’s stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday.

Anavex Life Sciences Stock Up 0.9 %

Shares of AVXL opened at $9.91 on Tuesday. The business’s 50-day moving average price is $9.95 and its 200-day moving average price is $7.49. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44. The stock has a market cap of $840.57 million, a PE ratio of -19.06 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Analysts expect that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.

Institutional Trading of Anavex Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of AVXL. Nwam LLC purchased a new stake in Anavex Life Sciences in the third quarter worth approximately $5,172,000. Renaissance Technologies LLC boosted its stake in shares of Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 386,537 shares during the period. Barclays PLC boosted its stake in shares of Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after purchasing an additional 64,101 shares during the period. Geode Capital Management LLC boosted its stake in shares of Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after purchasing an additional 51,946 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of Anavex Life Sciences during the second quarter valued at approximately $191,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.